[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 4 sources · 29 days · First seen · Last updated

European biotechnology and software funding trends

Overview

European biotechnology companies focusing on neurodegenerative diseases and regenerative medicine have secured various rounds of funding to advance clinical research and technology development.

In Belgium, Novadip Biosciences raised €10.4 million to support Phase 3 clinical trials for a cell-based therapy targeting congenital pseudarthrosis of the tibia. Concurrently, Remynd received €3.5 million from the Alzheimer’s Drug Discovery Foundation to fund a Phase 1b trial for REM392, a drug designed to improve synaptic function in Alzheimer’s patients.

In Germany, the biotech firm seragy secured 12 million euros to expand its SeRAS biomarker platform for diseases such as Parkinson’s and Alzheimer’s. This funding includes support from Commerzbank and the State of Lower Saxony, alongside a research grant from the Michael J. Fox Foundation. Additionally, the software startup SMYCLES raised 1.5 million euros to develop AI-driven tools for human-AI team optimization.

Entities

Michael J. Fox Foundation · seragy · European Investment Bank · bmp Ventures AG · Remynd

Timeline

  1. [BUSINESS] 2 sources
    German biotech and software startups secure new funding

    German companies seragy and SMYCLES have secured significant funding: seragy raised 12 million euros for neurodegenerative disease research, while SMYCLES raised 1.5 million euros for AI-driven team planning.

  2. [HEALTH] 2 sources
    Belgian biotech firms secure funding for clinical trials

    Belgian biotech firms Novadip Biosciences and Remynd have secured new funding to advance clinical trials for regenerative bone therapies and Alzheimer’s disease treatments.

Sources

european-biotechnology.com · healthcaremea.com · startbase.com · startbase.de